Media coverage about Enzo Biochem (NYSE:ENZ) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 46.4402769320728 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Enzo Biochem stock traded up $0.06 during mid-day trading on Thursday, reaching $4.06. The company’s stock had a trading volume of 49,900 shares, compared to its average volume of 167,296. Enzo Biochem has a 12 month low of $3.95 and a 12 month high of $11.50.
Enzo Biochem (NYSE:ENZ) last released its earnings results on Tuesday, June 12th. The medical research company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.04). The business had revenue of $25.63 million during the quarter. Enzo Biochem had a negative net margin of 4.12% and a negative return on equity of 6.31%.
Enzo Biochem Company Profile
Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.
Recommended Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.